1. Home
  2. BIVI vs VCIG Comparison

BIVI vs VCIG Comparison

Compare BIVI & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIVI
  • VCIG
  • Stock Information
  • Founded
  • BIVI 2013
  • VCIG 2013
  • Country
  • BIVI United States
  • VCIG Malaysia
  • Employees
  • BIVI N/A
  • VCIG N/A
  • Industry
  • BIVI Biotechnology: Pharmaceutical Preparations
  • VCIG Diversified Commercial Services
  • Sector
  • BIVI Health Care
  • VCIG Consumer Discretionary
  • Exchange
  • BIVI Nasdaq
  • VCIG Nasdaq
  • Market Cap
  • BIVI 15.1M
  • VCIG 15.6M
  • IPO Year
  • BIVI N/A
  • VCIG 2023
  • Fundamental
  • Price
  • BIVI $1.10
  • VCIG $4.18
  • Analyst Decision
  • BIVI Strong Buy
  • VCIG
  • Analyst Count
  • BIVI 1
  • VCIG 0
  • Target Price
  • BIVI $30.00
  • VCIG N/A
  • AVG Volume (30 Days)
  • BIVI 821.9K
  • VCIG 179.2K
  • Earning Date
  • BIVI 05-12-2025
  • VCIG 05-13-2025
  • Dividend Yield
  • BIVI N/A
  • VCIG 230.05%
  • EPS Growth
  • BIVI N/A
  • VCIG N/A
  • EPS
  • BIVI N/A
  • VCIG 54.73
  • Revenue
  • BIVI N/A
  • VCIG $27,819,290.00
  • Revenue This Year
  • BIVI N/A
  • VCIG N/A
  • Revenue Next Year
  • BIVI N/A
  • VCIG N/A
  • P/E Ratio
  • BIVI N/A
  • VCIG $0.09
  • Revenue Growth
  • BIVI N/A
  • VCIG 36.99
  • 52 Week Low
  • BIVI $0.62
  • VCIG $2.30
  • 52 Week High
  • BIVI $7.50
  • VCIG $1,097.60
  • Technical
  • Relative Strength Index (RSI)
  • BIVI 54.63
  • VCIG 38.37
  • Support Level
  • BIVI $1.05
  • VCIG $5.01
  • Resistance Level
  • BIVI $1.29
  • VCIG $6.05
  • Average True Range (ATR)
  • BIVI 0.14
  • VCIG 0.72
  • MACD
  • BIVI 0.03
  • VCIG 0.30
  • Stochastic Oscillator
  • BIVI 56.18
  • VCIG 6.50

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development solution consultancy. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology Consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment which focuses on listing solutions, investor relations, and boardroom strategies consultancy. It has established a diverse local and international clientele, providing them with its services in both local and cross-border listings. Its role begins with pre-listing diagnosis and planning to the finalization of the entire listing process.

Share on Social Networks: